Immunotherapy group TapImmune Inc (OTCMKTS:TPIV) plans to apply for a phase II trial of a new formulation of its HER2neu vaccine for breast cancer early next year.
The vaccine (TPIV 110) consists of four proprietary class II antigens and one proprietary class I antigen.
In the phase I trial, 90% patients developed a ‘robust- T-cell response’ to the class II antigens, while the class I antigen may be up to four time as more effective at killing breast cancer cells than those tested previously, research has suggested.
A combination of the antigens may be the best combination for a therapeutic response, added TapImmune.
An application to the US Food and Drug Admission for a clinical trial of the vaccine to include the new type 1 antigen peptide is expected around the end of the year.
“HER2neu is a well-known and important target in breast cancer treatments,” said Dr. John Bonfiglio, TapImmune’s chief executive.
“Our strategy is to highly leverage our HER2neu platform technology in treating this disease.”
Story by ProactiveInvestors